rs111513627
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 1P and 7B. PP2BP4_ModerateBP6BS2
The NM_004612.4(TGFBR1):c.214A>T(p.Ile72Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000256 in 1,613,910 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00019 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00026 ( 0 hom. )
Consequence
TGFBR1
NM_004612.4 missense
NM_004612.4 missense
Scores
9
9
Clinical Significance
Conservation
PhyloP100: 4.10
Genes affected
TGFBR1 (HGNC:11772): (transforming growth factor beta receptor 1) The protein encoded by this gene forms a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm. The encoded protein is a serine/threonine protein kinase. Mutations in this gene have been associated with Loeys-Dietz aortic aneurysm syndrome (LDAS). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
PP2
?
Missense variant where missense usually causes diseases, TGFBR1
BP4
?
Computational evidence support a benign effect (MetaRNN=0.1676732).
BP6
?
Variant 9-99128971-A-T is Benign according to our data. Variant chr9-99128971-A-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 178136.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=7, Likely_benign=5}. Variant chr9-99128971-A-T is described in Lovd as [Likely_benign].
BS2
?
High AC in GnomAd at 29 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TGFBR1 | NM_004612.4 | c.214A>T | p.Ile72Leu | missense_variant | 2/9 | ENST00000374994.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TGFBR1 | ENST00000374994.9 | c.214A>T | p.Ile72Leu | missense_variant | 2/9 | 1 | NM_004612.4 | P4 |
Frequencies
GnomAD3 genomes ? AF: 0.000191 AC: 29AN: 152198Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
29
AN:
152198
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000199 AC: 50AN: 250904Hom.: 0 AF XY: 0.000214 AC XY: 29AN XY: 135572
GnomAD3 exomes
AF:
AC:
50
AN:
250904
Hom.:
AF XY:
AC XY:
29
AN XY:
135572
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000263 AC: 384AN: 1461712Hom.: 0 Cov.: 31 AF XY: 0.000256 AC XY: 186AN XY: 727152
GnomAD4 exome
AF:
AC:
384
AN:
1461712
Hom.:
Cov.:
31
AF XY:
AC XY:
186
AN XY:
727152
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.000191 AC: 29AN: 152198Hom.: 0 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74348
GnomAD4 genome
?
AF:
AC:
29
AN:
152198
Hom.:
Cov.:
32
AF XY:
AC XY:
13
AN XY:
74348
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
2
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
3
ExAC
?
AF:
AC:
23
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:7Benign:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 14, 2023 | The TGFBR1 c.214A>T; p.Ile72Leu variant (rs111513627) is reported in the literature in several individuals affected with abdominal aortic aneurysm, bicuspid aortic valve, or a connective tissue disorder; however, its clinical significance was not demonstrated in these individuals (Bonachea 2014, van de Luijtgaarden 2015, Weerakkody 2016). In one family affected with aortic aneurysm, the p.Ile72Leu variant did not segregate with disease (van de Luijtgaarden 2015). This variant is found in the non-Finnish European population with an overall allele frequency of 0.03% (44/128734 alleles) in the Genome Aggregation Database. The isoleucine at codon 72 is highly conserved, but computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.351). Due to limited information, the clinical significance of the p.Ile72Leu variant is uncertain at this time. References: Bonachea EM et al. Use of a targeted, combinatorial next-generation sequencing approach for the study of bicuspid aortic valve. BMC Med Genomics. 2014 Sep 26;7:56. van de Luijtgaarden KM et al. First genetic analysis of aneurysm genes in familial and sporadic abdominal aortic aneurysm. Hum Genet. 2015 Aug;134(8):881-93. Weerakkody RA et al. Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome. Genet Med. 2016 Nov;18(11):1119-1127. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Blueprint Genetics | May 03, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 18, 2020 | This variant is associated with the following publications: (PMID: 26017485, 27153395) - |
Familial thoracic aortic aneurysm and aortic dissection Uncertain:1Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 01, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Jan 14, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Apr 05, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 17, 2023 | The p.I72L variant (also known as c.214A>T), located in coding exon 2 of the TGFBR1 gene, results from an A to T substitution at nucleotide position 214. The isoleucine at codon 72 is replaced by leucine, an amino acid with highly similar properties. This alteration has been detected in abdominal aortic aneurysm (AAA) and connective tissue disease cohorts, but was reported not to segregate with AAA in at least one family (van de Luijtgaarden KM et al. Hum. Genet., 2015 Aug;134:881-93; Weerakkody RA et al. Genet. Med., 2016 11;18:1119-1127). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 24, 2013 | Variant classified as Uncertain Significance - Favor Benign. The Ile72Leu varian t in TGFBR1 has not been reported in individuals with clinical features of Loeys -Dietz syndrome, but has been identified in 0.1% (1/1126) of chromosomes from a clinically and racially unspecified population, and in 0.03% (3/8600) of Europea n American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.wash ington.edu/EVS/; dbSNP rs111513627). While this frequency suggests that this var iant is more likely benign, it is too low to confidently rule out a disease caus ing role. Computational analyses (biochemical amino acid properties, conservatio n, AlignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an impact to the protein. In summary, additional information is needed to fully assess the clinical significance of the Ile72Leu variant. - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 19, 2023 | Variant summary: TGFBR1 c.214A>T (p.Ile72Leu) results in a conservative amino acid change located in the Activin types I and II receptor domain (IPR000472) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0002 in 250904 control chromosomes, predominantly at a frequency of 0.00036 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 290-fold of the estimated maximal expected allele frequency for a pathogenic variant in TGFBR1 causing Aortopathy phenotype (1.3e-06), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.214A>T has been reported in the literature in individuals affected with bicuspid aortic valve and unspecified connective tissue disease (Bonachea_2014, Weerakkody_2016), as well as abdominal aortic aneurysm in which the variant did not segregate in 1 family (van de Luijtgaarden_2015). These reports do not provide unequivocal conclusions about association of the variant with Aortopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Multiple submitters reported the variant with conflicting assessments. Based on the evidence outlined above, the variant was classified as likely benign. - |
Ehlers-Danlos syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Mar 16, 2022 | - - |
TGFBR1-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 26, 2023 | The TGFBR1 c.214A>T variant is predicted to result in the amino acid substitution p.Ile72Leu. This variant was reported as a variant of uncertain significance in two individuals with abdominal aortic aneurysms (van de Luijtgaarden et al. 2015. PubMed ID: 26017485) and in an individual with unspecified hereditary connective tissue disorder (Weerakkody et al. 2016. PubMed ID: 27011056). This variant resides outside of the serine-threonine kinase domain, which contains the majority of pathogenic missense variants (amino acids 206-496; Wrana et al. 1994. PubMed ID: 8047140). This variant is reported in 0.034% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-101891253-A-T) and has conflicting interpretations of likely benign and uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/178136/). Although we suspect this variant is more likely to be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
Cadd
Benign
Dann
Uncertain
DEOGEN2
Benign
T;T;D;.;.;T;.;.;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
D
MutationTaster
Benign
D;D;D;N
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N;N;N;N;N;N;.
REVEL
Uncertain
Sift
Uncertain
D;D;T;T;T;D;D;T;.
Sift4G
Uncertain
D;T;T;T;T;D;T;T;T
Polyphen
0.0, 0.026, 0.95
.;.;B;B;.;.;P;.;.
Vest4
0.35, 0.34, 0.34, 0.38
MutPred
0.52
.;.;Loss of catalytic residue at L77 (P = 0.062);Loss of catalytic residue at L77 (P = 0.062);Loss of catalytic residue at L77 (P = 0.062);.;.;.;.;
MVP
MPC
0.52
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at